Enginzyme and AGC unveil scalable process for key mRNA ingredient at Berlin Conference

PHARMEXCIL holds high-level talks with government to boost India’s pharma exports

India’s pharmaceutical sector stands at a pivotal inflection point

Valneva and Serum Institute end chikungunya vaccine partnership

Valneva said regaining full rights to the vaccine will allow the company to “assume direct control over its supply chain and commercialization for endemic high-risk countries

Elanco scores USDA nod for new canine allergy drug Befrena

Elanco expects Befrena to launch in the US in the first half of 2026

Sanofi to acquire Dynavax in $2.2 billion deal, bolstering adult vaccine portfolio

The move strengthens Sanofi’s presence in adult immunization by combining Dynavax’s innovative vaccines with Sanofi’s global scale and development capabilities

Biofabri and Bharat Biotech ink tech transfer pact to boost global TB vaccine access

BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia

Samsung Biologics strengthens U.S. presence with acquisition of GSK’s Human Genome Sciences or $280 million

Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs

Merck strikes historic deal with Trump admin to lower drug costs for Americans

Pfizer cuts 2026 revenue outlook amid COVID-19 & patent losses

The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion

Only 4-5 Indian pharma companies have a strong presence in Russia but the opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines